Sugi Predict

Sugi Predict / Compounds / SCHEMBL21201422

SCHEMBL21201422

SCHEMBL21201422

COC(=O)c1ccc(-c2cncc(Br)c2)c(Cl)c1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CYP2A6 P11509 1/20 0.43
▸ MAPK1 P28482 2/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ MAPT P10636 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ SLC2A1 P11166 1/20 0.43
▸ CYP11B1 P15538 2/20 0.42
▸ CYP11B2 P19099 2/20 0.42
▸ CYP19A1 P11511 1/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ HTT P42858 1/20 0.41
▸ ATM Q13315 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22977642 0.99 CYP2A6 (0.42) CYP2A6MAPK1ALDH1A1MAPTKDM4E
SCHEMBL28514780 0.95 ADH5 (0.45) CYP2A6MAPK1ALDH1A1MAPTKDM4E
SCHEMBL21201466 0.83 ADH5 (0.52) HTTTSHR
SCHEMBL23357794 0.81 PLAU (0.46) MAPK1ALDH1A1MAPTKDM4EMEN1
SCHEMBL22554086 0.80 CYP11B1 (0.51) MAPK1ALDH1A1MAPTKDM4EMEN1
SCHEMBL22977636 0.79 NOTUM (0.42) MAPK1ALDH1A1MAPTKDM4EMEN1
SCHEMBL21201316 0.78 ALPL (0.44) ALDH1A1MAPTKDM4ECYP11B1CYP11B2
SCHEMBL10028688 0.77 CYP11B2 (0.57) CYP2A6MAPK1ALDH1A1MAPTKDM4E
SCHEMBL21201237 0.77 ALDH1A1 (0.40) MAPK1ALDH1A1MAPTMEN1KMT2A
SCHEMBL23484572 0.76 SLC6A3 (0.54) ALDH1A1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11718628-B2 SREBP inhibitors comprising a 6-membered central ring CAPULUS THERAPEUTICS, LLC (US) 2023-08-08 — — US disclosed
US-11718628-B2 SREBP inhibitors comprising a 6-membered central ring CAPULUS THERAPEUTICS, LLC (US) 2023-08-08 — — US disclosed
US-20210047340-A1 SREBP INHIBITORS COMPRISING A 6-MEMBERED CENTRAL RING CAPULUS THERAPEUTICS, LLC 2021-02-18 — — US disclosed
CN-112243374-A SREBP inhibitors comprising a 6-membered central ring 卡普勒斯疗法有限责任公司 2021-01-19 — — CN disclosed
EP-3746070-A1 SREBP INHIBITORS COMPRISING A 6-MEMBERED CENTRAL RING Capulus Therapeutics, LLC (US) 2020-12-09 — — EP disclosed
WO-2019148125-A1 SREBP INHIBITORS COMPRISING A 6-MEMBERED CENTRAL RING CAPULUS THERAPEUTICS, LLC (US) 2019-08-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718628-B2 SREBP inhibitors comprising a 6-membered central ring SREBF1, SREBF2, XBP1 CYP2A6 353/4885MAPK1 1324/4885ALDH1A1 2993/4885
US-20210047340-A1 SREBP INHIBITORS COMPRISING A 6-MEMBERED CENTRAL RING SREBF1, SREBF2, XBP1 CYP2A6 353/4885MAPK1 1324/4885ALDH1A1 2993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.